The COCOON study randomized participants with previously untreated, EGFR-mutant, locally advanced or metastatic NSCLC undergoing intravenous amivantamab plus oral lazertinib treatment with enhanced dermatologic management (COCOON DM) and standard-of-care treatment (SoC DM) per local guidelines. This evidence concerns the gene EGFR and non-small cell lung carcinoma.